	DTX group	Control group	P-value
Number of patients	35	313
Months of follow-up, mean (range)	82.1 (8–152)	55.1 (1–180)
Age, mean (range)	66.0 (46–77)	74.5 (47–101)	P < 0.0001
PS
0	33	230	P = 0.0059
1 or greater	2	83
PSA ng/ml, mean (range)	480.6 (3.21–3 416)	878.1 (1.24–19362)	P = 0.2240
Gleason score
≤8	8	70	P = 0.9471
≥9	27	243
cT
≤T3a	19	149	P = 0.5674
≥T3b	16	164
cN
N0	12	119	P = 0.6655
N1	23	194
cM
M1a	4	50	P = 0.6464
M1b	25	223
M1c	6	40
Metastatic burden
Low	14	135	P = 0.8611
High	21	178

PS, Eastern Cooperative Oncology Group Performance Status; cT, clinical T-stage; cN, clinical N-stage; cM, clinical M-stage; PSA, prostatespecific antigen; DTX, docetaxel
Table 1: Baseline patient characteristics

	Univariate analysis			Multivariate analysis
	Odds	95% CI	P-value	Odds	95% CI	P-value
Age (<75/≥75)	0.795	0.633–0.998	0.0481	0.918	0.726–1.161	0.4763
PS (0/≥1)	0.719	0.551–0.937	0.0147	0.869	0.661–1.141	0.3124
PSA (<200/≥200)	0.655	0.520–0.824	0.0003	0.793	0.623–1.011	0.0607
cT (≤T3a/≥T3b)	0.804	0.639–1.013	0.0639
cN (N0/N1)	0.875	0.691–1.108	0.2668
Met. burden (low/high)	0.569	0.450–0.718	<0.0001	0.570	0.448–0.726	<0.0001
GS (≤8/≥9)	0.762	0.578–1.006	0.0549
DTX (y/n)	0.398	0.258–0.613	<0.0001	0.402	0.258–0.625	<0.0001

	Univariate analysis			Multivariate analysis
	Odds	95% CI	P-value	Odds	95% CI	P-value
Age (<75/≥75)	0.513	0.388–0.676	<0.0001	0.556	0.417–0.741	<0.0001
PS (0/≥1)	0.541	0.400–0.731	<0.0001	0.688	0.503–0.940	0.0188
PSA (< 200/≥200)	0.839	0.638–1.104	0.2102
cT (≤T3a/≥T3b)	0.838	0.636–1.105	0.2097
cN (N0/N1)	0.839	0.630–1.117	0.2289
Met. burden (low/high)	0.711	0.538–0.941	0.0170	0.698	0.526–0.927	0.0128
GS (≤8/≥9)	0.679	0.482–0.955	0.0260	0.660	0.468–0.930	0.0174
DTX (y/n)	0.442	0.256–0.761	0.0032	0.526	0.302–0.916	0.0233

	Univariate analysis			Multivariate analysis
	Odds	95% CI	P-value	Odds	95% CI	P-value
Age (<75/≥75)	0.837	0.584–1.200	0.3326
PS (0/≥1)	0.710	0.455–1.109	0.1321
PSA (<200/≥200)	0.907	0.626–1.316	0.6077
cT (≤T3a/≥T3b)	0.647	0.447–0.938	0.0216	0.775	0.528–1.137	0.1922
cN (N0/N1)	0.803	0.546–1.180	0.2637
GS (≤8/≥9)	0.631	0.404–0.986	0.0432	0.670	0.421–1.066	0.0910
DTX (y/n)	0.346	0.166–0.723	0.0048	0.366	0.173–0.776	0.0087

	Univariate analysis			Multivariate analysis
	Odds	95% CI	P-value	Odds	95% CI	P-value
Age (<75/≥75)	0.755	0.561–1.015	0.0630
PS (0/≥1)	0.792	0.569–1.103	0.1680
PSA (<200/≥200)	0.642	0.468–0.880	0.0059	0.702	0.511–0.964	0.0289
cT (≤T3a/≥T3b)	0.989	0.736–1.329	0.9406
cN (N0/N1)	0.850	0.629–1.147	0.2873
GS (≤8/ 9)	0.871	0.612–1.239	0.4412
DTX (y/n)	0.396	0.232–0.677	0.0007	0.429	0.250–0.736	0.0021

	Univariate analysis			Multivariate analysis
	Odds	95% CI	P-value	Odds	95% CI	P-value
Age (<75/≥75)	0.427	0.272–0.670	0.0002	0.492	0.302–0.770	0.0022
PS (0/≥1)	0.434	0.263–0.715	0.0011	0.546	0.325–0.918	0.0224
PSA (<200/≥200)	0.953	0.604–1.502	0.8346
cT (≤T3a/≥T3b)	0.378	0.436–1.056	0.0856
cN (N0/N1)	0.786	0.488–1.266	0.3224
GS (≤8/≥9)	0.618	0.355–1.075	0.0886
DTX (y/n)	0.367	0.134–1.004	0.0509

Tables at a glance

Figures at a glance

	Univariate analysis			Multivariate analysis
	Odds	95% CI	P-value	Odds	95% CI	P-value
Age (<75/≥75)	0.572	0.402–0.813	0.0019	0.613	0.428–0.877	0.0074
PS (0/≥1)	0.637	0.435–0.931	0.0200	0.740	0.502–1.091	0.1285
PSA (<200/≥200)	0.882	0.608–1.281	0.5105
cT (≤T3a/≥T3b)	1.016	0.713-1.448	0.9308
cN (N0/N1)	0.829	0.577–1.192	0.3115
GS (≤8/≥9)	0.713	0.462–1.100	0.1258
DTX (y/n)	0.462	0.241–0.884	0.0198	0.523	0.270–1.012	0.0542